Celiac Disease News and Research RSS Feed - Celiac Disease News and Research

Celiac disease is an inherited autoimmune disorder where gluten has been identified as the environmental trigger of the disease. Gluten is an ingested protein found in wheat, barley and rye. Gluten is broken down into gliadin which can pass through the intestinal epithelial barrier during times of increased intestinal permeability. The ingestion of gluten causes an immune response which triggers an inflammatory reaction in the small intestine. This then causes damage to the villi in the small intestine and can lead to total villous atrophy in celiac disease. This results in varying symptoms such as fatigue, skin rash, anemia, fertility issues, joint pain, weight loss, pale sores inside the mouth, tooth discoloration or loss of enamel, depression, chronic diarrhea or constipation, gas and abdominal pain. The immunology and nutritional abnormalities in celiac disease can potentially result in long- term complications such as osteoporosis, refractory sprue, small intestinal cancer, and lymphoma.

Celiac disease is a growing public health concern, affecting approximately 3 million people in the United States and over 6.5 million people worldwide. The only current management of celiac disease is complete elimination of gluten from the diet, which can be very difficult to implement in practice. Additionally, the response to the gluten-free diet is poor in up to 30% of patients, and dietary nonadherence is the chief cause of persistent or recurrent symptoms.

Prevalence of celiac disease on the rise among children with irritable bowel syndrome

There appears to be an increased prevalence of celiac disease among children with irritable bowel syndrome (IBS). [More]
New hypothesis about emergence of Parkinson's disease

New hypothesis about emergence of Parkinson's disease

The cause of neuronal death in Parkinson's disease is still unknown, but a new study proposes that neurons may be mistaken for foreign invaders and killed by the person's own immune system, similar to the way autoimmune diseases like type I diabetes, celiac disease, and multiple sclerosis attack the body's cells. [More]
BioLineRx to initiate Phase 1/2 clinical trial on new drug candidate for CML treatment

BioLineRx to initiate Phase 1/2 clinical trial on new drug candidate for CML treatment

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that Prof. Arnon Nagler, Director of the Hematology Division and Bone Marrow Transplantation Center at Sheba Medical Center, Israel, has received final regulatory approval to evaluate BioLineRx's BL-8040 as a treatment for chronic myeloid leukemia (CML) in a Phase 1/2 clinical study. [More]
Researchers show Elafin protein plays key role against inflammatory reaction typical of celiac disease

Researchers show Elafin protein plays key role against inflammatory reaction typical of celiac disease

Scientists from INRA and INSERM (France) in collaboration with scientists from McMaster University (Canada) and the Ecole polytechnique fédérale of Zurich (Switzerland) have shown that Elafin, a human protein, plays a key role against the inflammatory reaction typical of celiac disease (gluten intolerance). [More]

Discovery could lead to new therapies for people with celiac disease

Researchers at McMaster University have discovered a key molecule that could lead to new therapies for people with celiac disease, an often painful and currently untreatable autoimmune disorder. [More]
Celiac disease people may have near two-fold increased risk of coronary artery disease

Celiac disease people may have near two-fold increased risk of coronary artery disease

People with celiac disease may have a near two-fold increased risk of coronary artery disease compared with the general population, according to research to be presented at the American College of Cardiology's 63rd Annual Scientific Session. [More]
AJT describes novel approach to long-term tolerance in organ transplantation

AJT describes novel approach to long-term tolerance in organ transplantation

REGiMMUNE Corporation announced that the American Journal of Transplantation (AJT) has published its paper that describes a novel approach to long-term tolerance in organ transplantation with continuous administration of immune suppressants. [More]

Avaxia Biologics receives patent for oral anti-TNF antibodies for treatment of IBD

Avaxia Biologics, Inc., a clinical-stage biopharmaceutical company developing gut-targeted therapeutics, announced today that the company was awarded U.S. Patent No. 8,647,626, entitled "Compositions Comprising TNF-specific Antibodies for Oral Delivery." [More]

Alba Therapeutics reports positive results from Phase IIb trial of larazotide acetate for CeD treatment

Alba Therapeutics Corporation announced today the positive results of their Phase IIb trial evaluating its investigational product, larazotide acetate, a first-in-class tight junction regulator, intended for the treatment of patients with celiac disease (CeD). [More]
BioLineRx's BL-8040 gets FDA Orphan Drug Designation for stem cell mobilization treatment

BioLineRx's BL-8040 gets FDA Orphan Drug Designation for stem cell mobilization treatment

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has received notice from the U.S. Food & Drug Administration confirming an Orphan Drug Designation of BL-8040 as a treatment for stem cell mobilization, in addition to the Orphan Drug Designation previously granted to BL-8040 as a treatment for Acute Myeloid Leukemia. [More]

Adding quinoa to gluten-free diet of patients with celiac disease is well-tolerated

Adding quinoa to the gluten-free diet of patients with celiac disease is well-tolerated, and does not exacerbate the condition, according to new research published in The American Journal of Gastroenterology. Dr. Victor F. Zevallos, from the Department of Gastroenterology, King's College London, United Kingdom, evaluated the in-vivo effects of consuming quinoa in adult celiac patients. Quinoa, a highly nutritious grain, is traditionally recommended as part of a gluten-free diet. [More]

BioLineRx gets approval to begin CE Mark registration trial of BL-5010P for skin lesion treatment

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has received approval from the German Federal Institute for Drugs and Medical Devices (BfArM) to commence a pivotal, CE Mark registration trial for BL-5010P, for the non-surgical removal of benign skin lesions. [More]
Genotyping strategy could boost celiac screening efficacy

Genotyping strategy could boost celiac screening efficacy

Genotyping for human leukocyte antigen followed by biopsy is a sensitive strategy for detecting histopathologic lesions in the close relatives of people with celiac disease, research indicates. [More]
Six common diseases arise from DNA changes, finds new research

Six common diseases arise from DNA changes, finds new research

Many rare disorders are caused by gene mutation, like sickle cell anemia. Yet until now the underlying genetic cause of more common conditions - for example, rheumatoid arthritis - has evaded scientists for years. [More]

BioLineRx enrolls first patient in BL-7010 Phase 1/2 trial for treatment of celiac disease

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today enrollment of the first patient in a Phase 1/2 trial of BL-7010, for the treatment of celiac disease. The first patient was enrolled at Tampere Hospital in Finland, a world-leading site for celiac disease research. Results are expected in mid-2014. [More]
BioLineRx reports promising initial results from Phase 2 trial of BL-8040 in AML patients

BioLineRx reports promising initial results from Phase 2 trial of BL-8040 in AML patients

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today promising initial results for its BL-8040 drug candidate in a Phase 2 clinical trial for patients with relapsed or refractory acute myeloid leukemia (AML). [More]

Research paper highlights experiences, results of celiac disease screening in young children

Most children who undergo screening to detect gluten intolerance, celiac disease, can handle it well. However, many people feel that the discovery of the disease and the treatment they receive does not provide a better quality of life. [More]

BioLineRx obtains regulatory approval to initiate BL-7010 Phase 1/2 trial for celiac disease

BioLineRx, a biopharmaceutical development company, announced today that it has received regulatory approval from the Finnish National Supervisory Authority for Welfare and Health (Valvira) to commence a Phase 1/2 safety trial for BL-7010, for the treatment of celiac disease. [More]
Researchers develop new interactive software game to help children with peanut allergies

Researchers develop new interactive software game to help children with peanut allergies

Elizabeth McQuaid, Ph.D., a staff psychologist from the Bradley Hasbro Children's Research Center, is leading a research team testing a new interactive software game developed to help children with peanut allergies better manage allergy symptoms, social situations and proper food avoidance. [More]
IBS Treatment Center opens new clinic in Santa Monica, California

IBS Treatment Center opens new clinic in Santa Monica, California

The IBS Treatment Center, which specializes in treating irritable bowel syndrome, announced the opening of a new clinic in Santa Monica, California, in late October. Conveniently located next to the UCLA Medical Center, this new branch of the clinic will provide a progressive approach to digestive health as well as easy access to treatment for patients previously without adequate care. [More]